EUVIMEDEUVIMED entdecken
Open Access

Carrier-free Arg-CpG augments antitumor efficacy by triggering specific immune activation

Huishan Li iD, Quankun Lin iD, Yuexia Xie iD, Xiaozhen He iD, Shuai Yang, Yan Zhou, Xue Zhao iD, Xingang Wang, Yongming Han iD, Fangli Cao iD, Lu Gan iD, Sidi Zhang iD und 1 weitere

Science Advances · 13.11.2026 · 12 (46)

DOI: 10.1126/sciadv.aeg8936 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science Advances, erschienen am 13.11.2026. Verfasst von Huishan Li und 12 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Systems Medicine for Cancer, Shanghai Cancer Institute, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, S…. Hauptthemen laut MEDLINE: Oligodeoxyribonucleotides, Antineoplastic Agents, Peptides, Neoplasms. Die Arbeit nennt 52 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Natural Science Foundation of Shanghai, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The delivery of nucleic acids using nonviral vectors represents a promising approach for cancer therapy. Nevertheless, nucleic acid–based drugs suffer from poor potency and rapid degradation. Herein, we report a carrier-free nucleic acid delivery system termed Arg-CpG, which is easily constructed through charge-driven assembly of poly( l -arginine) (Arg) and the immune adjuvant unmethylated cytosine-phosphate-guanine oligonucleotide (CpG). This Arg-CpG functions as both a carrier and a therapeutic agent, thereby eliminating the need for a conventional drug delivery vehicle and minimizing potential toxicity. The guanidinium groups of Arg endow Arg-CpG with dual functionalities: enhancing cellular uptake and serving as the nitrogen donor for iNOS-mediated nitric oxide (NO) generation. This NO production further synergizes with CpG to drive macrophage reprogramming toward an antitumor phenotype. Notably, Arg-CpG exhibits cell-type–dependent modulation of autophagy. It disrupts autophagic machinery in 4T1 tumor cells while preserving functional autophagy in RAW264.7 macrophages. This differential activity results in selective killing of tumor cells without compromising the viability or function of normal immune cells. Consequently, Arg-CpG elicits a robust antitumor immune response in vivo. Moreover, the modular design of Arg-CpG enables its straightforward assembly with CpG oligonucleotides and other nucleic acid payloads (e.g., anti-miR oligonucleotides and siRNA), establishing a versatile and promising platform for nucleic acid–based cancer therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

OligodeoxyribonucleotidesAntineoplastic AgentsPeptidesNeoplasmsAnimalsMiceNitric OxideMacrophagesHumansAutophagyCell Line, TumorRAW 264.7 CellsArginine

Substanzen

OligodeoxyribonucleotidesNitric OxideAntineoplastic AgentsCPG-oligonucleotidePeptidespolyarginineArginine

Autor:innen und Institutionen

  • State Key Laboratory of Systems Medicine for Cancer, Shanghai Cancer Institute, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200032, China.
  • Department of Medical Oncology, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
  • Department of Liver Surgery, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200127, China.
  • Central Laboratory, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200127, China.
  • Department of Medical Oncology, Qilu Hospital of Shandong University (Qingdao), Qingdao 266000, China.
  • Shanghai Key Laboratory of Cancer System Regulation and Clinical Translation, Jiading District Central Hospital, Renji Hospital Jiading Branch, Shanghai 201800, China.

ORCID-Profile: Huishan Li, Quankun Lin, Yuexia Xie, Xiaozhen He, Xue Zhao, Yongming Han, Fangli Cao, Lu Gan, Sidi Zhang, Peifeng Liu

Förderung

  • Natural Science Foundation of Shanghai
  • National Natural Science Foundation of China

Zitieren

APA

Li, H., Lin, Q., Xie, Y., He, X., Yang, S., Zhou, Y., Zhao, X., Wang, X., Han, Y., Cao, F., Gan, L., Zhang, S., & Liu, P. (2026). Carrier-free Arg-CpG augments antitumor efficacy by triggering specific immune activation. Science Advances, 12(46). https://doi.org/10.1126/sciadv.aeg8936

Vancouver

Li H, Lin Q, Xie Y, He X, Yang S, Zhou Y, et al. Carrier-free Arg-CpG augments antitumor efficacy by triggering specific immune activation. Science Advances. 2026;12(46). doi:10.1126/sciadv.aeg8936

BibTeX
@article{Li2026,
  author = {Li, Huishan and Lin, Quankun and Xie, Yuexia and He, Xiaozhen and Yang, Shuai and Zhou, Yan and Zhao, Xue and Wang, Xingang and Han, Yongming and Cao, Fangli and Gan, Lu and Zhang, Sidi and Liu, Peifeng},
  title = {Carrier-free Arg-CpG augments antitumor efficacy by triggering specific immune activation},
  journal = {Science Advances},
  year = {2026},
  volume = {12},
  number = {46},
  doi = {10.1126/sciadv.aeg8936}
}
Kostenlos starten →